LGVN ▼ -3.1% - Longeveron Inc.
$LGVN LGVNR - Longeveron Announces Updated Results from ELPIS II Phase 2b Clinical Trial Evaluating Laromestrocel as a Potential Treatment for Hypoplastic Left Heart Syndrome (HLHS)
26-OCT-2026 09:15 AM ET
Share this post
More filings for $LGVN
LGVN - Longeveron Inc. - SEC Filing Update (13-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 13, 2026LGVN ▼ -10.0% - Longeveron Inc.Nov 12, 2026LGVN - Longeveron Inc. - SEC Filing Update (05-NOV-2026) | ThinkSabio - Stocks SimplifiedNov 6, 2026LGVN ▲ +4.6% - Longeveron Inc.Oct 28, 2026LGVN ▼ -1.1% - Longeveron Inc.Sep 30, 2026LGVN ▼ -2.6% - Longeveron Inc.Sep 16, 2026
View full $LGVN filing history →💬 Comments
Loading comments…
Leave a comment